U.S. Small Molecule Drug Discovery Outsourcing Market Size Worth USD 3.68 Billion by 2034 | CAGR: 9.48%

The U.S small molecule drug discovery outsourcing market size is expected to reach USD 3.68 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Small Molecule Drug Discovery Outsourcing Market Share, Size, Trends, Industry Analysis Report By Workflow (Target Identification & Screening, Target Validation & Functional Informatics), By Service, By Therapeutics Area, By End Use; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Small molecule drug discovery outsourcing involves partnering with external organizations, such as contract research organizations (CROs), to accelerate and optimize the drug development process. These collaborations help pharmaceutical and biotech companies access specialized expertise, advanced technologies, and cost-effective solutions while reducing in-house burdens. Outsourced services include target identification, hit-to-lead optimization, preclinical testing, and medicinal chemistry. Small molecule drug discovery outsourcing is particularly valuable for small firms with limited infrastructure or large companies seeking flexible R&D capabilities. Outsourcing also enables access to innovative platforms such as AI-driven drug design and high-throughput screening through next-generation sequencing, enhancing efficiency in discovering novel therapeutics for diseases such as cancer, metabolic disorders, and infectious diseases.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/us-small-molecule-drug-discovery-outsourcing-market/request-for-sample

The U.S. dominates small molecule drug discovery outsourcing due to its robust biopharma ecosystem, research facilities, and a high concentration of CROs. American companies outsource to both domestic and international partners to leverage cost efficiencies and specialized expertise, particularly in medicinal chemistry, computational modeling, and preclinical development. The U.S. market emphasizes quality, regulatory compliance, and rapid innovation, driving demand for integrated outsourcing solutions. Trends such as AI-powered drug discovery and sustainable chemistry are shaping the market, with hubs such as Boston and San Francisco leading collaborations.

U.S. Small Molecule Drug Discovery Outsourcing Market Report Highlights

• In terms of workflow, the lead identification & candidate optimization segment accounted for a major revenue share in 2024 due to increasing reliance of pharmaceutical and biotechnology companies on external partners for early-stage compound discovery.
• Based on service, the chemistry services segment dominated the revenue share in 2024 due to high demand for medicinal and synthetic chemistry in the early stages of drug discovery.
• In terms of therapeutic area, the oncology segment held the largest revenue share in 2024 due to the high prevalence of cancer and the urgent demand for targeted and personalized therapies.
• The central nervous system segment is expected to grow at a robust pace during the forecast period, owing to the growing investments in the development of treatments for neurodegenerative diseases, psychiatric disorders, and epilepsy.
• A few major companies operating in the U.S. small molecule drug discovery outsourcing market include Charles River Laboratories; Curia Global, Inc.; Eurofins Scientific; Evotec; GenScript Biotech; Labcorp; Merck & Co., Inc.; Oncodesign; Pharmaron; and Syngene International.

Polaris Market Research has segmented the U.S. small molecule drug discovery outsourcing market report on the basis of workflow, service, therapeutic area, and end use:

By Workflow Outlook (Revenue, USD Billion, 2020–2034)

• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Others

By Service Outlook (Revenue, USD Billion, 2020–2034)

• Chemistry Services
• Biology Services

By Therapeutic Area Outlook (Revenue, USD Billion, 2020–2034)

• Respiratory System
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System

By End Use Outlook (Revenue, USD Billion, 2020–2034)

• Pharmaceutical & Biotechnology Companies
• Academic Institutes